Overview
Goodwin Procter advised on 779 venture deals in 2025 according to PitchBook, third worldwide.[1] The firm describes its focus as six industries: healthcare, investment funds, life sciences, private equity, real estate and technology.[8] That mix gives it unusual depth on the investor side, since it acts for many private-equity and venture fund managers, and in biotechnology, where financings involve licensing, clinical-stage milestones and later public offerings. Goodwin is a common choice for life-sciences startups in the Boston and Cambridge cluster and for technology companies whose investors are already Goodwin fund clients. As with other large full-service firms, standard hourly rates apply once early-stage fee arrangements end.
Goodwin strengths and limitations
Strengths
- Deep life-sciences and biotech financing experience
- Large investment-funds practice gives insight into investor terms
Limitations
- Fund-side relationships can raise conflicts for company clients
- Deal volume less than Gunderson or Cooley, so less benchmarking data on small rounds
Appears in
Goodwin alternatives and competitors
Alternatives to Goodwin: companies ranked in the same lists.
Gunderson Dettmer
Cooley- Orrick
- Wilson Sonsini Goodrich & Rosati
- DLA Piper
Silicon Legal Strategy- Pillsbury Winthrop Shaw Pittman
Latham & Watkins
Fenwick & West
Is this your company?
Update the description, logo, image and link through the submission form. Editors review every change.